Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1Genitourinary 1

Conditions

Salivary Gland Neoplasms 1Prostatic Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 284Specimen Handling 278pembrolizumab 255Cyclophosphamide 234Radiotherapy 224Nivolumab 182Cisplatin 172Biopsy 163Carboplatin 152Radiosurgery 139fludarabine 128Blood Specimen Collection 128Surveys and Questionnaires 117Gemcitabine 117Paclitaxel 114Standard of Care 110venetoclax 109Dexamethasone 103Bevacizumab 96Radiation 92Rituximab 89Oxaliplatin 86Capecitabine 86Cytarabine 85Drug Therapy 83Ipilimumab 81Doxorubicin 81durvalumab 80atezolizumab 74fludarabine phosphate 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Androgen Receptor Antagonists × 90 days × Clear all
NCT04946370 2026-04-21

Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

Weill Medical College of Cornell University

Phase 1/2 Recruiting
52 enrolled
Genitourinary

Prostatic Neoplasms

NCT06145308 2026-04-02

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Peking Union Medical College

Phase 2 Recruiting
39 enrolled
Head & Neck

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡